Nexaph Reta is a research-grade retatrutide peptide sold for lab use only. See how it compares with cagrilintide and MOTS-c, plus safety and legal facts.
Nexaph Reta is a research-grade retatrutide peptide sold by the vendor Nexaph for laboratory use only. Retatrutide is an investigational triple agonist that targets GLP-1, GIP, and glucagon receptors at the same time, and it is not FDA-approved for human use in the United States. Anyone who lands on the phrase "nexaph reta" while shopping for a weight-loss injection is looking at a research chemical listing, not a prescription medication.
The term combines a supplier and a molecule. "Nexaph" is the seller, and "reta" is shorthand for retatrutide, the compound Eli Lilly is studying in its Phase 3 TRIUMPH program. Vendors ship it as a lyophilized powder in sealed vials, and the label almost always carries a "for research use only" disclaimer.
What Is Nexaph Reta, Exactly?
Nexaph is one of many online suppliers that sell peptides marketed to laboratories rather than patients. Its retatrutide listing is a single-compound product, not a blend, and it is typically sold in milligram vials of freeze-dried powder that must be reconstituted before use.
Here is what the typical listing includes:
- A stated purity level, most often 98% or higher, based on HPLC testing
- A mass spectrometry result confirming the molecular weight
- A lot or batch number that should match the certificate of analysis
- A "not for human or veterinary use" statement
Nexaph also lists nexaph lipo-c, a lipotropic blend of methionine, inositol, and choline, which works through a completely different and largely unproven mechanism. Lipo-C injections are promoted in some clinics as fat-burning shots, but the FDA has not approved them for weight loss.
How Retatrutide Works in Research Models
Retatrutide is classified as a triple agonist because it binds three receptors instead of one. GLP-1 activity is linked to appetite suppression and slower gastric emptying, GIP activity is linked to insulin sensitivity and fat metabolism, and glucagon activity is linked to energy expenditure.
That third receptor is what separates retatrutide from semaglutide and tirzepatide in the literature. Researchers study it as a way to test whether adding glucagon signaling improves metabolic outcomes beyond what dual agonists produce in animal models.
How it differs from cagrilintide
Cagrilintide is an amylin analog, which means it works through a completely different satiety pathway in the brain and gut. Scientists comparing cagrilintide with retatrutide are usually asking whether amylin signaling and incretin signaling stack, not whether one is stronger than the other.
Most of the cagri reta blend benefits discussed in forums are anecdotal, and no approved product contains both compounds. Reported reta cagri blend side effects mirror the gastrointestinal profile of GLP-1 drugs in general: nausea, vomiting, diarrhea, and injection-site irritation.
How Nexaph Reta Compares With Other Research Peptides
| Compound | Receptor targets | Main research focus | Regulatory status |
|---|---|---|---|
| Retatrutide (reta) | GLP-1, GIP, glucagon | Metabolic and body-weight signaling | Investigational; not FDA-approved |
| Cagrilintide | Amylin and calcitonin receptors | Satiety and appetite regulation | Investigational; not FDA-approved |
| MOTS-c | Mitochondrial-derived peptide pathways | Metabolic homeostasis, exercise adaptation | Research use only; not a drug |
| Lipo-C (MIC blend) | Methionine, inositol, choline | Lipotropic and liver-support claims | Not FDA-approved for weight loss |
A reta vs mots-c comparison usually comes down to mechanism rather than potency. Retatrutide acts on gut and pancreatic hormone receptors, while MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied for metabolic flexibility and exercise mimicry.
Data on mots-c and reta used together in humans is essentially nonexistent. No published trial has combined the two, so any claim about stacking them is extrapolation from separate studies, not evidence.
Quality Control: What a Certificate of Analysis Should Show
Purity claims are only as good as the lab that made them. Researchers should look for third-party testing rather than vendor-generated numbers, and should verify that the lot number on the vial matches the lot number on the report.
A useful certificate of analysis typically includes:
- HPLC purity percentage with the chromatogram attached
- Mass spectrometry data confirming identity
- Testing laboratory name and accreditation
- Sterility and endotoxin results, which are frequently missing
Batch-to-batch variation is common in the gray-market peptide supply chain, so a strong report from one lot does not guarantee the next one.
Safety Signals and Legal Status
In early-phase retatrutide trials, the most common adverse events were nausea, diarrhea, vomiting, and constipation, with some participants also showing increases in resting heart rate. Those findings come from supervised clinical settings with medical monitoring, which is not how research peptides are typically handled outside a lab.
Retatrutide is not FDA-approved for human use in the United States. A "research use only" label does not make personal use legal, and the FDA has repeatedly warned about unapproved and compounded GLP-1 products entering the market. Importing unapproved peptides for personal use can also create customs and legal exposure.
| Factor | Research-use peptide | FDA-approved medicine |
|---|---|---|
| Regulatory review | None | Required before sale |
| Human dosing guidance | Not established | Defined in labeling |
| Manufacturing oversight | Vendor-dependent | Enforced by regulators |
| Legal personal use | Generally not permitted | Allowed with a prescription |
Anyone weighing a metabolic treatment should speak with a licensed healthcare professional rather than relying on vendor pages or forum reports. Research chemicals are sold to generate data, not to treat patients, and the two contexts carry very different risks.
Frequently Asked Questions
Is Nexaph Reta FDA-approved?
No. Nexaph Reta is retatrutide sold as a research-use-only chemical, and retatrutide is not FDA-approved for human use in the United States. It remains an investigational drug being studied in clinical trials.
What is the difference between reta and MOTS-c?
Retatrutide is a synthetic triple agonist that acts on GLP-1, GIP, and glucagon receptors. MOTS-c is a mitochondrial-derived peptide studied for metabolic and exercise-related pathways. They work through unrelated mechanisms, and no human trial has tested them together.
What is in a cagri reta blend?
A cagri reta blend combines cagrilintide, an amylin analog, with retatrutide, a triple receptor agonist. Neither compound is FDA-approved, and no approved medication contains both. Reported side effects are mainly gastrointestinal, including nausea and vomiting.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.